Our results indicate that AdipoRs dual agonist JT003 with a longer half-life could ameliorate NASH and related liver fibrosis via AMPK, PPARα and PI3K-Akt signal pathways. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatohepatitis.